 Emergent BioSolutions Inc NYSE: EBS will resume production of Johnson Johnsons NYSE: JNJ COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated. The development comes after JJ last week slashed the 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce 1 billion shots. 